Atomwise

Atomwise is at the forefront of using artificial intelligence to transform drug discovery and create better medicines. The company has developed a machine learning-based discovery engine that combines the power of convolutional neural networks with massive chemical libraries to discover new small molecule medicines. Atomwise's AI-enabled discovery portfolio includes both wholly owned and co-developed pipeline assets, backed by prominent investors. Their approach aims to reinvent drug discovery by leveraging AI to make the process faster, more efficient, and more likely to succeed. The company's AtomNet® platform is designed to screen billions of compounds to identify those with the highest potential to treat specific diseases. Atomwise has established numerous partnerships with pharmaceutical companies, biotechnology firms, and academic institutions to apply its technology across a wide range of therapeutic areas. The company's focus on combining AI with traditional drug discovery expertise has positioned it as a leader in the field of AI-driven pharmaceutical research and development.